STX17 Gene

STX17 — Syntaxin 17

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">STX17 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>STX17</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Syntaxin 17</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>9q31.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>55276</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>612598</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000143891</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9NYQ6</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">STX17 stabilizers</td>
<td>Enhance SNARE complex formation</td>
</tr>
<tr>
<td class="label">Autophagy inducers</td>
<td>Upstream pathway activation</td>
</tr>
<tr>
<td class="label">Lysosomal enhancers</td>
<td>Improve final degradation step</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/bacterial-infection" style="color:#ef9a9a">Bacterial Infection</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-5e68b4ad" style="color:#ce93d8" title="Score: 0.47">Autophagosome Maturat

STX17 — Syntaxin 17

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">STX17 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>STX17</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Syntaxin 17</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>9q31.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>55276</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>612598</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000143891</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9NYQ6</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">STX17 stabilizers</td>
<td>Enhance SNARE complex formation</td>
</tr>
<tr>
<td class="label">Autophagy inducers</td>
<td>Upstream pathway activation</td>
</tr>
<tr>
<td class="label">Lysosomal enhancers</td>
<td>Improve final degradation step</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/bacterial-infection" style="color:#ef9a9a">Bacterial Infection</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-5e68b4ad" style="color:#ce93d8" title="Score: 0.47">Autophagosome Maturation Checkpoint Cont...</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">754 edges</a></td>
</tr>
</table>

Pathway Diagram

Introduction

STX17 (Syntaxin 17) is a SNARE protein encoded by the STX17 gene located on chromosome 9q31.3. It is a member of the syntaxin family of SNARE (Soluble N-ethylmaleimide-sensitive factor Attachment Protein Receptor) proteins that mediate membrane fusion. [@stx]

STX17 is a critical component of the [autophagy](/entities/autophagy) machinery, specifically required for autophagosome-lysosome fusion. Mutations in STX17 are associated with [Parkinson's disease](/diseases/parkinsons-disease) and [dementia with Lewy bodies](/diseases/dementia-with-lewy-bodies).[@stx] [@stxa]

The protein encoded by STX17 is [STX17 Protein](/proteins/stx17-protein).[@stxa] [@stxb]

--- [@syntaxin]

Overview

STX17 is a tail-anchored SNARE protein that localizes primarily to the outer membrane of autophagosomes. Unlike other syntaxins that function at the plasma membrane or Golgi, STX17 has evolved to specialize in autophagy. [@autophagylysosome2016]

Key functions include:

• Autophagosome-lysosome fusion: Essential for autophagy completion
• ER-mitochondria contact: Maintains cellular homeostasis
• Lipid droplet dynamics: Affects lipid metabolism

Gene Structure

Protein Structure and Function

Domain Architecture

STX17 contains:

• N-terminal regulatory region: Autophagy-related functions
• SNARE domain: Membrane fusion machinery
• Transmembrane anchor: Tail-anchored membrane protein

SNARE Complex Formation

STX17 forms a SNARE complex with:

• VAMP8: Lysosomal v-SNARE
• SNAP29: Adapter SNARE
• STX17: Autophagosomal t-SNARE

Biological Functions

Autophagy

STX17 is essential for:

• Autophagosome maturation: Recruitment of lysosomes
• Selective autophagy: Mitophagy, xenophagy
• Cargo delivery: Complete autophagic flux

ER-Mitochondria Tethering

STX17 maintains:

• Mitochondria-ER contacts: MAM (mitochondria-associated membranes)
• Calcium homeostasis: Calcium transfer between organelles
• Lipid exchange: Phospholipid metabolism

Cellular Homeostasis

Through autophagy:

• Protein aggregate clearance
• Organelle quality control
• Cellular stress response

Expression in the Brain

Neuronal Expression

STX17 is expressed in:

• Dopaminergic [neurons](/entities/neurons): Substantia nigra pars compacta
• Cerebral [cortex](/brain-regions/cortex): Pyramidal neurons
• [Hippocampus](/brain-regions/hippocampus): All regions
• Cerebellum: Purkinje cells
• Motor neurons: Spinal cord

Cellular Localization

In neurons:

• Autophagosomes: Throughout soma and processes
• Lysosomes: Perinuclear and distal
• Synaptic terminals: Regulates local autophagy
• Mitochondria: MAM localization

Disease Associations

Parkinson's Disease

STX17 is strongly linked to PD:

• Mutations identified: Splice site, I45V
• Inheritance: Autosomal dominant
• Mechanism: Impaired autophagy
• Pathogenesis: [α-Synuclein](/proteins/alpha-synuclein) accumulation

• [Alpha-Synuclein](/proteins/alpha-synuclein) aggregation
• [PINK1](/genes/pink1)/[PARKIN](/genes/parkin) mitophagy
• [Lysosomal dysfunction](/mechanisms/lysosomal-dysfunction)

Dementia with Lewy Bodies (DLB)

• STX17 variants associated with DLB
• Autophagy-lysosome pathway dysfunction
• α-Synuclein Lewy body formation

Alzheimer's Disease

• Altered autophagic flux
• Amyloid processing connections
• [Tau](/proteins/tau) clearance mechanisms

Other Neurodegenerative Diseases

• Huntington's disease
• Amyotrophic lateral sclerosis
• Prion diseases

Pathogenic Mechanisms

Autophagy Dysfunction

STX17 mutations cause:

Protein Aggregate Accumulation

Due to autophagy defects:

• α-Synuclein inclusions
• Damaged mitochondria
• ER stress

Neuronal Vulnerability

Dopaminergic neurons are particularly susceptible:

• High basal autophagy demand
• Complex axonal morphology
• Oxidative stress exposure

Therapeutic Approaches

Autophagy Enhancement

• Autophagy inducers (rapamycin, metformin)
• [TFEB](/entities/tfeb) (transcription factor EB) activators
• Lysosomal function enhancers

Small Molecule Modulators

• SNARE complex stabilizers
• Autophagy-specific compounds
• Lysosomal activity promoters

Gene Therapy

• AAV-STX17 delivery
• CRISPR-based approaches
• Small interfering RNA

Combination Therapies

• Autophagy induction + α-synuclein reduction
• Neuroprotective + disease-modifying
• Personalized medicine approaches

Research Models

Cellular Models

• Patient-derived iPSC neurons
• Dopaminergic cell lines
• Primary neuron cultures

Animal Models

• Stx17 knockout mice
• Parkinson's disease models
• Transgenic STX17 mutants

Biochemical Studies

• SNARE complex purification
• Autophagic flux measurements
• Live-cell imaging

Clinical Relevance

Genetic Testing

• STX17 sequencing for PD diagnosis
• Variant interpretation
• Family screening

Biomarkers

• Autophagic flux markers
• Lysosomal function tests
• CSF biomarkers

Therapeutic Development

• Autophagy modulators in trials
• Target validation needed
• Patient selection strategies

See Also

• [STX17 Protein](/proteins/stx17-protein)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Dementia with Lewy Bodies](/diseases/dementia-with-lewy-bodies)
• [Autophagy in Neurodegeneration](/mechanisms/autophagy)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [SNARE Proteins](/entities/snare-proteins)

External Links

• [NCBI Gene: STX17](https://www.ncbi.nlm.nih.gov/gene/55276)
• [UniProt: STX17](https://www.uniprot.org/uniprot/Q9NYQ6)
• [OMIM: STX17](https://omim.org/entry/612598)
• [PDGene: STX17](https://www.pdgene.org/)

Background

The study of Stx17 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

Structural Biology of STX17

Domain Architecture

STX17 is a 299-amino acid tail-anchored SNARE protein with distinct structural features [@stxb]:

• N-terminal regulatory domain: Contains the N-terminal region (NTD) that regulates SNARE complex formation and prevents premature assembly
• SNARE domain: The central SNARE motif (residues 150-250) mediates polymerization into SNARE complexes
• Transmembrane anchor: The C-terminal transmembrane domain (residues 270-299) anchors STX17 to membranes

SNARE Complex Formation

STX17 forms a canonical four-helical SNARE complex with specific partners [@yamaguchi2019]:

The assembly follows a specific order:

• STX17 first binds SNAP29 in the cytosol
• The binary complex then recruits VAMP8 on lysosomes
• Formation of the four-helical bundle drives membrane fusion

Auto-Inhibitory Regulation

STX17 is regulated by auto-inhibitory mechanisms:

• N-terminal occlusion: The NTD blocks the SNARE motif in resting state
• Phosphorylation: STX17 is phosphorylated at specific serine residues, regulating its activity
• Interaction with regulatory proteins: Various proteins modulate STX17 function

STX17 in Autophagosome-Lysosome Fusion

The Final Fusion Step

STX17 is essential for the last step of macroautophagy [@heo2015]:

Selective Autophagy

STX17 also mediates selective autophagy pathways:

• Mitophagy: Damaged mitochondria are cleared via STX17-dependent fusion
• Xenophagy: Intracellular pathogens are eliminated
• Aggrephagy: Protein aggregates are removed

Autophagosome Biogenesis

Beyond fusion, STX17 contributes to autophagosome formation [@fang2020]:

• ER-Golgi intermediate compartment: STX17 participates in early autophagosome formation
• Isolation membrane expansion: Supports membrane expansion events
• Cargo loading: Ensures proper cargo recruitment

STX17 at ER-Mitochondria Contact Sites

MAM Localization

STX17 localizes to mitochondria-associated membranes (MAM), ER-mitochondria contact sites [@knoblach2013]:

• MAM function: These contact sites facilitate calcium transfer, lipid exchange
• STX17 at MAM: Controls ER-mitochondria tethering and signaling
• Calcium homeostasis: STX17 helps regulate mitochondrial calcium uptake

Interorganelle Communication

STX17 coordinates communication between organelles:

• ER-mitochondria signaling: Links ER stress to mitochondrial responses
• Lipid droplet dynamics: Regulates lipid storage and mobilization
• Apparatus assembly: Coordinates organelle dynamics for quality control

STX17 in Synaptic Function

Presynaptic Localization

STX17 is present at presynaptic terminals [@mediros2022]:

• Synaptic vesicle pools: Controls synaptic vesicle recycling
• Neurotransmitter release: Regulates release probability
• Synaptic plasticity: Supports long-term synaptic changes

Activity-Dependent Autophagy

At synapses, STX17-mediated autophagy responds to activity:

• Synaptic remodeling: Autophagy clears synaptic components during plasticity
• Protein turnover: Maintains synaptic protein homeostasis
• Presynaptic protection: Removes damaged proteins from terminals

STX17 Mutations and Disease

Parkinson's Disease

STX17 mutations cause autosomal dominant PD [@stx]:

• Mutation types: Splice site mutations, missense variants
• Penetrance: Variable, age-dependent
• Phenotype: Classic PD with typical onset around age 60

Dementia with Lewy Bodies

STX17 is implicated in DLB pathogenesis [@saito2019]:

• Genetic variants: Associated with increased risk
• Pathology: STX17 in Lewy bodies
• Mechanism: Impaired autophagy-lysosome pathway

Other Neurodegenerative Conditions

• Alzheimer's disease: Altered STX17 in AD brains
• Huntington's disease: STX17 dysfunction contributes to pathology
• ALS: STX17 in motor neuron disease

Therapeutic Targeting of STX17

Autophagy Enhancement

Modulating STX17 function for therapeutic benefit [@guadagno2023]:

Small Molecule Modulators

• SNARE complex enhancers: Promote functional complex formation
• Phosphorylation modulators: Target regulatory sites
• Fusion promoters: Facilitate membrane fusion

Gene Therapy Approaches

• AAV-STX17: Overexpression for function restoration
• CRISPR approaches: Correct pathogenic mutations
• siRNA: Allele-specific silencing if needed

Combination Strategies

• Autophagy + aggregation inhibitors: Multi-target approaches
• Gene therapy + small molecules: Additive benefits
• Synaptic protection + autophagy: Comprehensive neuroprotection

Model Systems for STX17 Research

Cellular Models

• Knockout cell lines: Loss-of-function studies
• Patient-derived neurons: iPSC models with STX17 mutations
• Overexpression systems: Gain-of-function analysis

Animal Models

• STX17 knockout mice: Show neuropathology
• Conditional knockouts: Tissue-specific deletion
• Mutant knock-in models: Patient mutation carriers

Organoid Models

• Brain organoids: 3D culture systems
• Dopaminergic neurons: PD-relevant models
• Synaptic organoids: Studies of synaptic function

STX17 as a Biomarker

Genetic Testing

STX17 sequencing for:

• Diagnostic confirmation: Confirm PD diagnosis
• Family screening: Cascade testing for at-risk relatives
• Prognostic information: Disease course prediction

Functional Biomarkers

• Autophagic flux markers: Monitor pathway activity
• Lysosomal function tests: Assess downstream function
• SNARE complex assembly: Measure STX17 activity

Therapeutic Monitoring

• Treatment response: Track autophagy enhancement
• Disease progression: Monitor functional decline
• Clinical trials: Outcome measure development

Clinical Considerations

When to Test for STX17

Genetic testing is recommended for:

• Early-onset PD: Age <50 with family history
• Atypical presentations: DLB with early motor symptoms
• Family screening: Relatives of mutation carriers

Management Implications

For patients with STX17 variants:

• Standard PD treatment: Levodopa, dopamine agonists
• Autophagy-enhancing strategies: Lifestyle modifications
• Monitoring: Regular neurological assessment

Family Counseling

• Autosomal dominant inheritance: 50% transmission risk
• Variable penetrance: Not all carriers develop disease
• Reproductive options: Preimplantation genetic testing

Emerging Research Directions

Structural Studies

• Cryo-EM of SNARE complexes: High-resolution structures
• Conformational dynamics: Real-time assembly monitoring
• Small molecule interactions: Drug binding sites

Systems Biology

• Protein interactomics: New STX17 partners
• Phosphoproteomics: Regulatory phosphorylation sites
• Metabolomics: Metabolic consequences of dysfunction

Clinical Translation

• Biomarker development: Fluid and imaging markers
• Clinical trials: STX17-targeted interventions
• Personalized medicine: Genotype-guided therapy

Conclusion

STX17 (Syntaxin 17) is a specialized SNARE protein that plays critical roles in autophagy completion and interorganelle communication. Its mutations cause familial Parkinson's disease and contribute to other neurodegenerative conditions. As the SNARE protein mediating autophagosome-lysosome fusion, STX17 represents a key therapeutic target for enhancing cellular clearance in neurodegeneration. Strategies to maintain or enhance STX17 function—through small molecules, gene therapy, or combination approaches—hold promise for developing disease-modifying treatments for PD, DLB, and related disorders. The continued investigation of STX17's broader cellular functions, including its roles at ER-mitochondria contact sites and synapses, will further our understanding of neuronal health and disease.

STX17 in Cellular Stress Responses

Oxidative Stress

STX17 responds to oxidative stress conditions:

• Activation under stress: Oxidative stress enhances STX17 expression
• Protection mechanism: Autophagy induction protects neurons
• Disease relevance: Oxidative stress is a key PD driver

ER Stress Response

STX17 coordinates with the unfolded protein response [@insausti2021]:

• ER-mitochondria crosstalk: Links ER stress to mitochondrial quality control
• Apoptosis regulation: Controls cell death decisions under stress
• Disease implications: ER stress is prominent in neurodegeneration

Metabolic Regulation

STX17 affects cellular metabolism [@shibuya2022]:

• Lipid droplet metabolism: Regulates cellular lipid stores
• Mitochondrial function: Maintains metabolic fitness
• Energy balance: Coordinates cellular energetics

STX17 and Other Neurodegeneration Genes

Genetic Interactions

STX17 interacts with other PD genes:

• LRRK2: Functional interactions in autophagy
• GBA: Lysosomal pathway coordination
• SNCA: Alpha-synuclein clearance relationships
• PINK1/Parkin: Mitophagy pathway coordination

Network Effects

STX17 participates in broader cellular networks:

• Retromer pathway: Endosomal trafficking connections
• Autophagy-lysosome pathway: Central role in final fusion
• SNARE machinery: Core fusion machinery

Future Perspectives

Basic Research Priorities

• Structure-function studies: High-resolution STX17 structures
• Regulatory mechanisms: Understanding control of STX17 activity
• Cell-type specificity: How STX17 function varies by cell type

Therapeutic Development

• Target validation: Confirm STX17 as viable target
• Small molecule discovery: High-throughput screening for activators
• Delivery optimization: Improving CNS penetration

Biomarker Development

• Fluid biomarkers: CSF and blood markers
• Imaging biomarkers: PET ligands for STX17
• Functional biomarkers: Autophagic flux measurements

Summary

STX17 represents a unique SNARE protein essential for cellular clearance through autophagy. Its discovery as a PD-causing gene highlights the importance of the autophagy-lysosome pathway in neuronal health. The continued exploration of STX17 function and dysfunction will provide essential insights into neurodegenerative disease mechanisms and therapeutic opportunities.

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Autophagosome Maturation Checkpoint Control](/hypothesis/h-5e68b4ad) — <span style="color:#ffd54f;font-weight:600">0.47</span> · Target: STX17

Pathway Diagram

The following diagram shows the key molecular relationships involving STX17 Gene discovered through SciDEX knowledge graph analysis: